Impacto clínico del PET/TC Ga68-DOTATOC en tumores de origen neuroendocrino. Experiencia preliminar

Körner, 2016, Specific biology of neuroendocrine tumors: Peptide receptors as molecular targets, Best Pract Res Clin Endocrinol Metab., 30, 19, 10.1016/j.beem.2016.01.001 Lloyd, 2017 Yao, 2008, One hundred years after ‘carcinoid’: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States, J Clin Oncol., 26, 3063, 10.1200/JCO.2007.15.4377 Agencia Española de Medicamentos y Productos Sanitarios. Informe mensual sobre medicamentos de uso humano y productos sanitarios. Informe de posicionamiento terapéutico de edotreotida (SomaKit TOC®) en la localización de tumores neuroendocrinos gastroenteropancreáticos bien diferenciados. Junio 2018. Ficha técnica de SomaKit TOC 40 microgramos equipo de reactivos para preparación radiofarmacéutica [18 Ene 2019]. Disponible en: http://www.ema.europa.eu/docs/es ES/document_library/EPAR -Product_Information/human/004140/WC500221851.pdf Gabriel, 2007, 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT, J Nucl Med., 48, 508, 10.2967/jnumed.106.035667 Ambrosini, 2010, 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors, J Nucl Med., 51, 669, 10.2967/jnumed.109.071712 Plaza, 2004, Valoración de un tumor neuroendocrino mediante gammagrafía 111In-pentetreótido y PET con 18F-FDopa y 18F-FDG, Rev Esp Med Nucl., 23, 421, 10.1016/S0212-6982(04)72332-0 Suárez-Piñera, 2019, PET/TC imaging with somatostatin analogues for assessment of neuroendocrine tumors, initial experience, Rev Esp Med Nucl Imagen Mol., 38, 382 Delle Fave, 2016, ENETS Consensus guidelines update for gastroduodenal neuroendocrine neoplasms, Neuroendocrinology., 103, 119, 10.1159/000443168 Garcia-Carbonero, 2016, ENETS Consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas, Neuroendocrinology., 103, 186, 10.1159/000443172 Hope, 2018, Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors, J Nucl Med., 59, 66, 10.2967/jnumed.117.202275 Mojtahedi, 2014, The value of (68) Ga-DOTATATE PET/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature, Am J Nucl Med Mol Imaging., 4, 426 Virgolini, 2010, Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE, Eur J Nucl Med Mol Imaging., 37, 2004, 10.1007/s00259-010-1512-3 Hofman, 2015, Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation, Radiographics., 35, 500, 10.1148/rg.352140164 Sadowski, 2016, Prospective study of 68Ga-DOTATATE positron emission tomography/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites, J Clin Oncol., 34, 588, 10.1200/JCO.2015.64.0987 Van Binnebeek, 2016, Comparison of diagnostic accuracy of 111In-pentetreotide SPECT and 68Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours, Eur Radiol., 26, 900, 10.1007/s00330-015-3882-1 Bodei, 2018, Somatostatin receptor imaging of neuroendocrine tumors: from agonists to antagonists, J Nucl Med., 59, 907, 10.2967/jnumed.117.205161 Etchebehere, 2014, 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial, J Nucl Med., 55, 1598, 10.2967/jnumed.114.144543 Hosono, 2018, Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed), Ann Nucl Med., 32, 217, 10.1007/s12149-018-1230-7 Castinetti, 2015, 15 years of paraganglioma: Imaging and imaging-based treatment of pheochromocytoma and paraganglioma, Endocr Relat Cancer., 22, T135, 10.1530/ERC-15-0175 Archier, 2016, Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases, Eur J Nucl Med Mol Imaging., 43, 1248, 10.1007/s00259-015-3268-2 Janssen, 2015, Superiority of [68Ga]-DOTATATE PET/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma, Clin Cancer Res., 21, 3888, 10.1158/1078-0432.CCR-14-2751